Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial.

Authors:
  • EME Marzo
    E Marzo
  • GLG Longombardo
    G Longombardo
  • FLF Lombardini
    F Lombardini
  • LCL La Civita
    L La Civita
  • RVR Vanacore
    R Vanacore
  • ALA M Liberati
    A M Liberati
  • RGR Gerli
    R Gerli
  • FGF Greco
    F Greco
  • AMA Moretti
    A Moretti
  • MMM Monti
    M Monti
  • PGP Gentilini
    P Gentilini

  • 1 March 1993
    • journal article
    • clinical trial
    • Vol. 81  (5) , 1132-6
    • PMID:8382969
Abstract
The effects of interferon-alpha (IFN-alpha) on clinical and serologic manifestations of mixed cryoglobulinemia (MC) were investigated by randomized, crossover-controlled trial in 26 patients. The trial alternated 6 months with and 6 months without IFN-alpha therapy (2 x 10(6) IU daily for a month, then every other day for 5 months). In 22 patients, pretreatment steroid dosage remained unchanged during the study. Six patients dropped out (three because of side effects), whereas another 20 patients experienced a significant improvement of purpura (P < .02) and serum transaminases (P < .005) during IFN-alpha treatment. The presence of clinical improvement was supported by the outcome measurements of several immunologic parameters. In particular, serum cryoglobulins were significantly reduced (P < .04) during IFN-alpha therapy. A rebound phenomenon of clinical and serologic parameters was observed after IFN-alpha discontinuation. In addition, no variations were recorded during 6 months without therapy. Hepatitis C virus (HCV) RNA was detected in 91% (20/22) of our MC patients; in 2/13 cases HCV RNA was no longer detectable in serum samples after IFN-alpha therapy. Thus, IFN-alpha could be considered as treatment for MC in patients with HCV seropositivity.